Loading
Life sciences · Journal article
Cancer Science · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT In advanced non‐squamous non‐small cell lung cancer (non‐sq NSCLC), companion diagnostic testing (CDx) identifies actionable driver alterations and guides initial targeted therapy. However, disease progression inevitably occurs through acquired resistance, including activation of bypass signaling pathways. Although comprehensive genomic profiling (CGP) can identify emerging resistance alterations, its clinical utility in patients with known actionable driver alterations remains unclear. We retrospectively analyzed 227 patients who underwent CGP between June 2019 and August 2025. Patients with actionable driver alterations identified by CDx before CGP formed the known driver group. We also analyzed the nationwide C‐CAT registry to assess registry‐recorded therapeutic implementation. Among 227 patients, 74 (32.6%) had known actionable driver alterations. CGP identified additional clinically relevant genomic findings, including ESCAT Tier I–III or V alterations, in 34 patients (45.9%), comparable to that in patients without known actionable driver alterations (77/153, 50.3%). In the EGFR ‐mutated ( EGFR m) subgroup, CGP frequently identified alterations consistent with potential bypass resistance mechanisms, including MET amplification, RET fusions, and BRAF V600E mutations. Overall, 10 patients (13.5%) received CGP‐guided therapy based on additional findings, all within the EGFR m subgroup, whereas no patients with non‐ EGFR driver alterations did. In the C‐CAT registry, CGP‐associated therapy was documented in 21 of 381 (5.5%) in the EGFR m subgroup, 6 of 155 (3.9%) in the non‐ EGFR driver subgroup, and 195 of 2132 (9.1%) without registry‐defined driver alterations. These findings indicate that CGP provides molecular re‐evaluation during disease progression, particularly by identifying alterations consistent with potentially actionable resistance or bypass mechanisms in EGFR m NSCLC.